Supplying take home naloxone without a prescription

AI Summary

This guidance outlines the expanded distribution of naloxone, an opioid overdose antidote, under the UK Human Medicines (Amendment) Regulations of 2015, 2019, and 2024. The legislative framework enables specific professionals and registered services to supply naloxone without a prescription to save lives in emergencies involving substances like heroin, fentanyl, and nitazenes. Key manufacturers mentioned include Ethypharm, Napp, and Accord, with wholesale distribution handled by AAH Pharmaceuticals and Alliance Healthcare. As this is a guidance document rather than an enforcement report, no specific company violations or inspection dates are recorded. The framework establishes two routes for supply: Route 1 covers named professionals such as police, prison staff, nurses, and pharmacists; Route 2 applies to other services subject to a forthcoming registration process. Required actions for participating entities include implementing robust clinical governance and mandatory training for both staff and recipients. Training must cover overdose identification, emergency service coordination, and product administration. Although naloxone remains a prescription-only medicine, it may be supplied to individuals at risk, their families, or outreach workers. For recipients under 18, supply must follow clinical principles and consider marketing authorizations—noting that while Nyxoid is authorized for ages 14 and over, other formulations are typically for adults. Additionally, services must maintain detailed records for stock management, monitoring, and product replacement upon expiry. Safe storage and local funding arrangements are also essential components of the compliance framework.